Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Carisma Therapeutics (NASDAQ:CARM – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, earnings and dividends.
Profitability
This table compares Xeris Biopharma and Carisma Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | 3.81% | 735.00% | 3.24% |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
Valuation & Earnings
This table compares Xeris Biopharma and Carisma Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | 4.55 | $550,000.00 | $0.06 | 128.17 |
| Carisma Therapeutics | $10.77 million | 0.03 | -$60.48 million | $0.73 | 0.01 |
Xeris Biopharma has higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Xeris Biopharma has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Institutional and Insider Ownership
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Xeris Biopharma and Carisma Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 2 | 4 | 0 | 2.43 |
| Carisma Therapeutics | 1 | 0 | 1 | 1 | 2.67 |
Xeris Biopharma currently has a consensus price target of $10.80, indicating a potential upside of 40.44%. Carisma Therapeutics has a consensus price target of $1.00, indicating a potential upside of 12,245.68%. Given Carisma Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than Xeris Biopharma.
Summary
Xeris Biopharma beats Carisma Therapeutics on 8 of the 15 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
